Recombinant Rat CX3CL1 protein (rFc Tag)(HPLC verified)

Species

Rat

Purity

>90 %, SDS-PAGE
>90 %, SEC-HPLC

Tag

rFc Tag

Activity

not tested

Cat no : Eg3280

---

Validation Data Gallery

• 

  Purity of Recombinant Rat CX3CL1 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

• 

  The purity of Rat CX3CL1 was greater than 90% as determined by SEC-HPLC.

---

Product Information

• Purity: >90 %, SDS-PAGE; >90 %, SEC-HPLC
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Rat CX3CL1 protein Thr30-Arg335 (Accession# O55145) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 89808
• Accession: O55145
• PredictedSize: 58.8 kDa
• SDS-PAGE: 70-100 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Fractalkine/CX3C chemokine ligand 1 (CX3CL1) is a chemokine involved in the anticancer function of lymphocytes—mainly NK cells, T cells and dendritic cells. CX3CL1 has a cysteine signature motif -Cys-X-X-X-Cys- at the N-terminal end and is the only known representative of the δ-chemokine family. CX3CL1 shows high expression in the brain, where it is synthesized by neurons and has neuroprotective functions. High expression of CX3CL1 is also found in the kidneys, lungs, bones and blood vessels.

References:

1. Liu W,  et al. (2016). Arch Immunol Ther Exp.Oct;64(5):371-83. 
2. Korbecki J, et al. (2020). Int J Mol Sci. May 25;21(10):3723. 
3. Conroy M.J., et al. (2020). Adv Exp Med Biol. 1231:1-12.